SPIE conference - Feb. 2020Neither TLT nor UHN are presenting @SPIE in February 2020.
Not necessarly surprizing considering that they presented 10 papers late June 2019. Maybe they want to wait for more Ph. 2b data to be released before returning there as far as the NMIBC indication is concerned.
One that captured my attention though is this one:
Saturday 1 February 2020 ...
Saturday 1 February 2020
12:20 PM - 2:40 PM
Introducing outpatient PDD and IMAGE1-S guided diode laser treatment of intermediate-risk non-invasive bladder tumors to the outpatient department: optic diagnosis is needed for immediate treatment Paper 11212-10 Author(s): Gregers G. Hermann, Marie S. Erikson, Karin Mogensen, Herlev Hospital (Denmark) A new laser method was developed to remove bladder tumors during flexible cystoscopy without sedation.
Efficacy of laser treatment was evaluated endoscopically after 1, 4 and 12 months. Treatment pain, post-procedure symptoms, future worries and economic analysis of outpatient laser treatment was performed. All patients preferred laser treatment. Adverse events negligible. 91% of patients had no remnant tumour tissue at 1 month follow up. 9% had benign flat low-grade dysplasia. No disease progression.
1): Outpatient laser treatment without sedation of superficial bladder tumors is safe and efficient.
2): Urologists still have to wait 5-7 days for histological diagnosis of tumor, which delay tumor treatment.
Optic diagnostic modalities as OCT or Raman spectrometry are needed for immediate diagnosis of tumor stage during cystoscopy allowing immediate treatment of tumor. We invite to collaboration here about.